arrow
M

Mauro Tettamanti

mario negri institute for pharmacologic research irccs
H指数:50
被引数:8,392

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

In-hospital antibiotic consumption in Lombardy, Italy (2017–2024): a retrospective analysis of regional administrative data

意大利伦巴第大区2017–2024年院内抗生素消耗量:一项区域行政数据的回顾性分析

2026-09-070
OAAI
Prescription of SGLT-2 inhibitors alone or in combination with RAS-inhibitors in patients with diabetes mellitus and comorbid cardiovascular disease, chronic kidney disease or cardiorenal disease: a real-world evidence study from the REPOSI registry

糖尿病合并心血管疾病、慢性肾脏病或心肾疾病患者单独或联合使用SGLT-2抑制剂与RAS抑制剂的处方:来自REPOSI注册研究的真实世界证据研究

2026-08-250
PRE
JNK3 quantification in plasma: a novel biomarker for neuronal damage in Parkinson’s disease

血浆中JNK3的定量分析:帕金森病神经元损伤的一种新型生物标志物

2025-12-100
OA
Specialist Healthcare Intervention and Follow-up Trends in Post-Acute COVID-19 Hospitalization as Compared to Other Respiratory Infections

与其它呼吸道感染相比,专科医疗干预和随访趋势在急性COVID-19后住院治疗中的表现

2025-10-270
OA
The remote administration of the uniform data set neuropsychological test battery (I-UDSNB) Italian version: normative data

统一数据集神经心理学测试组合(I-UDSNB)意大利版:远程管理及常模数据

2025-09-200
OA
Tolerability of vortioxetine compared to selective serotonin reuptake inhibitors in older adults with major depressive disorder (VESPA): a randomised, assessor-blinded and statistician-blinded, multicentre, superiority trial

老年重度抑郁症 (VESPA) 患者对沃替西汀与选择性5-羟色胺再摄取抑制剂的耐受性比较: 一项随机,评估盲和统计学家盲的多中心优越性试验

2024-03-012
OAAI